BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) announced today the shipping of a new instrument that offers laboratories a more affordable, low-throughput option for analyzing the quality of RNA and DNA samples.

Forbes announced that Westlake Village BioPartners founding managing director Beth Seidenberg, MD, has been ranked 59 on the annual Midas List of the world’s top 100 technology venture capitalists.

The U.S. Department of Agriculture, the U.S. Environmental Protection Agency, and the Food and Drug Administration kick off Winning on Reducing Food Waste Month by calling for greater collaboration with public, private, and nonprofit partners as well as state and local officials to educate and engage consumers and stakeholders throughout the supply chain on the need to reduce food loss and waste.

In its 10th year, Cleveland Clinic’s annual Patient Experience: Empathy + Innovation Summit is partnering with global health information thought leader HIMSS.

Clinical stage biotechnology company Que Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flashes and night sweats, tested at key sites in the United States.

Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, announced today that it will be presenting preclinical data at the American Association for Cancer Research Annual Meeting in Atlanta, Georgia on April 3, 2019.

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers, today presented new preclinical data on its lead program ORIC-101, a selective and potent glucocorticoid receptor (GR) antagonist, at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA.

Revealing the impressive growth and impact of the technology sector in Arizona and the U.S., Arizona Technology Council partner CompTIA released its Cyberstates 2019 report, the definitive annual analysis of the nation’s tech industry.

Nektar Therapeutics presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin, a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research Annual Meeting 2019.

AmorChem, a leading venture fund dedicated to creating the next generation of biotech companies derived from academic research, introduced its rebranding this week.